Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.

"Conflicts of interest statement Drs Alphs, Fu, Bossie, and Sliwa are employees of Ortho-McNeil Janssen Scientific Affairs, Titusville, New Jersey, and Dr Ma is an employee of Johnson and Johnson Pharmaceutical Research and Development (PRD), Titusville, New Jersey."

"Funding This research was funded by Ortho-McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA."

"Editorial support was provided by Susan Ruffalo, PharmD, MedWrite, Inc., Newport Coast, California. The authors would like to acknowledge the contributions of J. Thomas Haskins, PhD of Johnson & Johnson PRD, Titusville, New Jersey in the development of these analyses. All authors provided assistance and direction in the data collection and analysis of this study, and in the preparation of the manuscript. These data were presented at the American Psychiatric Association Annual Meeting, 22–26 May 2010. This study is registered at ClinicalTrials.gov (NCT00590577)."